SIROLIMUS vs TACROLIMUS

Compare SIROLIMUS (sirolimus) and TACROLIMUS (Tacrolimus) — clinical data, side effects, and patient experiences.

SIROLIMUS

sirolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimul...

Approved for

1.2

it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids

peak PRA level > 80%])

it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration ( 2.3 )

OralTablet

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

Quick Comparison

SIROLIMUSTACROLIMUS

Drug Class

Immunosuppressant

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SIROLIMUS

Drug Not Working

>10%

Fever

1-10%

Diarrhea

1-10%

Condition Worsened

0.1-1%

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

SIROLIMUS

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions ( 5
12 ) Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic Microangiopathy ( 5
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis
Many of these patients had evidence of infection at or near the time of death

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

Clinical Trial Data

No head-to-head clinical studies found for SIROLIMUS vs TACROLIMUS.

SIROLIMUS vs TACROLIMUS: What You Should Know

Key Differences

Both SIROLIMUS and TACROLIMUS belong to the Immunosuppressant class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

SIROLIMUS carries 4 FDA warnings. TACROLIMUS carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EVEROLIMUS vs SIROLIMUS→CYCLOSPORINE OPHTHALMIC SOLUTION vs SIROLIMUS→CYCLOSPORINE vs SIROLIMUS→MYCOPHENILIC ACID vs SIROLIMUS→EVEROLIMUS vs TACROLIMUS→AZATHIOPRINE vs SIROLIMUS→

Loading comparison data...

SIROLIMUS vs TACROLIMUS

Compare SIROLIMUS (sirolimus) and TACROLIMUS (Tacrolimus) — clinical data, side effects, and patient experiences.

SIROLIMUS

sirolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimul...

Approved for

1.2

it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids

peak PRA level > 80%])

it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [ see Dosage and Administration ( 2.3 )

OralTablet

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

Quick Comparison

SIROLIMUSTACROLIMUS

Drug Class

Immunosuppressant

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SIROLIMUS

Drug Not Working

>10%

Fever

1-10%

Diarrhea

1-10%

Condition Worsened

0.1-1%

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

SIROLIMUS

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions ( 5
12 ) Increased Risk of Calcineurin Inhibitor-Induced Hemolytic Uremic Syndrome/ Thrombotic Thrombocytopenic Purpura/ Thrombotic Microangiopathy ( 5
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections such as tuberculosis, fatal infections, and sepsis
Many of these patients had evidence of infection at or near the time of death

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

Clinical Trial Data

No head-to-head clinical studies found for SIROLIMUS vs TACROLIMUS.

SIROLIMUS vs TACROLIMUS: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.